177lu-psma-617
novartis
['#vision', 'vision trial']
radiographic progression-free survival correlation with time-to-event endpoints: a post hoc analysis of the #vision trial. presented by . #esmo22 written coverage by on urotoday &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology